<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_CSBJ1163 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEmmc1 xlsx ?>
<?FILEmmc2 xlsx ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Comput Struct Biotechnol J</journal-id>
    <journal-id journal-id-type="iso-abbrev">Comput Struct Biotechnol J</journal-id>
    <journal-title-group>
      <journal-title>Computational and Structural Biotechnology Journal</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2001-0370</issn>
    <publisher>
      <publisher-name>Research Network of Computational and Structural Biotechnology</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8385119</article-id>
    <article-id pub-id-type="pii">S2001-0370(21)00347-0</article-id>
    <article-id pub-id-type="doi">10.1016/j.csbj.2021.08.016</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>TSNAD v2.0: A one-stop software solution for tumor-specific neoantigen detection</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au005">
        <name>
          <surname>Zhou</surname>
          <given-names>Zhan</given-names>
        </name>
        <email>zhanzhou@zju.edu.cn</email>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="af020" ref-type="aff">d</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <contrib contrib-type="author" id="au010">
        <name>
          <surname>Wu</surname>
          <given-names>Jingcheng</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="af010" ref-type="aff">b</xref>
        <xref rid="fn1" ref-type="fn">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au015">
        <name>
          <surname>Ren</surname>
          <given-names>Jianan</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au020">
        <name>
          <surname>Chen</surname>
          <given-names>Wenfan</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="af030" ref-type="aff">f</xref>
      </contrib>
      <contrib contrib-type="author" id="au025">
        <name>
          <surname>Zhao</surname>
          <given-names>Wenyi</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="af010" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author" id="au030">
        <name>
          <surname>Gu</surname>
          <given-names>Xun</given-names>
        </name>
        <xref rid="af015" ref-type="aff">c</xref>
      </contrib>
      <contrib contrib-type="author" id="au035">
        <name>
          <surname>Chi</surname>
          <given-names>Ying</given-names>
        </name>
        <xref rid="af025" ref-type="aff">e</xref>
      </contrib>
      <contrib contrib-type="author" id="au040">
        <name>
          <surname>He</surname>
          <given-names>Qiaojun</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="af020" ref-type="aff">d</xref>
      </contrib>
      <contrib contrib-type="author" id="au045">
        <name>
          <surname>Yang</surname>
          <given-names>Bo</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="af020" ref-type="aff">d</xref>
      </contrib>
      <contrib contrib-type="author" id="au050">
        <name>
          <surname>Wu</surname>
          <given-names>Jian</given-names>
        </name>
        <email>wujian2000@zju.edu.cn</email>
        <xref rid="af010" ref-type="aff">b</xref>
        <xref rid="af020" ref-type="aff">d</xref>
        <xref rid="af035" ref-type="aff">g</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <contrib contrib-type="author" id="au055">
        <name>
          <surname>Chen</surname>
          <given-names>Shuqing</given-names>
        </name>
        <email>chenshuqing@zju.edu.cn</email>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <aff id="af005"><label>a</label>Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</aff>
      <aff id="af010"><label>b</label>Collaborative Innovation Center of Artificial Intelligence by MOE and Zhejiang Provincial Government, College of Computer Science and Technology, Zhejiang University, Hangzhou 310027, China</aff>
      <aff id="af015"><label>c</label>Department of Genetics, Development and Cell Biology, Iowa State University, Ames, IA 50011, USA</aff>
      <aff id="af020"><label>d</label>Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310018, China</aff>
      <aff id="af025"><label>e</label>Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Alibaba DAMO Academy, Hangzhou 311121, China</aff>
      <aff id="af030"><label>f</label>Polytechnic Institute, Zhejiang University, Hangzhou 310015, China</aff>
      <aff id="af035"><label>g</label>Real Doctor AI Research Centre, School of Medicine, Zhejiang University, Hangzhou 310058, China</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>⁎</label>Corresponding authors at: College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China (Z. Zhou, S. Chen). College of Computer Science and Technology, Zhejiang University, Hangzhou 310027, China (J. Wu). <email>zhanzhou@zju.edu.cn</email><email>wujian2000@zju.edu.cn</email><email>chenshuqing@zju.edu.cn</email></corresp>
      <fn id="fn1">
        <label>1</label>
        <p id="np005">Authors who contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>12</day>
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <volume>19</volume>
    <fpage>4510</fpage>
    <lpage>4516</lpage>
    <history>
      <date date-type="received">
        <day>1</day>
        <month>4</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>10</day>
        <month>8</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>10</day>
        <month>8</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2021 The Author(s)</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="ab005">
      <p>TSNAD is a one-stop software solution for predicting neoantigens from the whole genome/exome sequencing data of tumor-normal pairs. Here we present TSNAD v2.0 which provides several new features such as the function of RNA-Seq analysis including gene expression and gene fusion analysis, the support of different versions of the reference genome. Most importantly, we replace the NetMHCpan with DeepHLApan we developed previously, which considers both the binding between peptide and major histocompatibility complex (MHC) and the immunogenicity of the presented peptide-MHC complex (pMHC). TSNAD v2.0 achieves good performamce on a standard dataset. For better usage, we provide the Docker version and the web service of TSNAD v2.0. The source code of TSNAD v2.0 is freely available at <ext-link ext-link-type="uri" xlink:href="https://github.com/jiujiezz/tsnad" id="ir005">https://github.com/jiujiezz/tsnad</ext-link>. And the web service of TSNAD v2.0 is available at <ext-link ext-link-type="uri" xlink:href="http://biopharm.zju.edu.cn/tsnad/" id="ir010">http://biopharm.zju.edu.cn/tsnad/</ext-link>.</p>
    </abstract>
    <kwd-group id="kg005">
      <title>Keywords</title>
      <kwd>Neoantigens</kwd>
      <kwd>Somatic mutations</kwd>
      <kwd>Major histocompatibility complex</kwd>
      <kwd>Tumor immunotherapy</kwd>
      <kwd>One-stop software</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="s0005">
    <label>1</label>
    <title>Introduction</title>
    <p id="p0005">Tumor neoantigens which are derived from mutated proteins and presented on the surface of cancer cells are tumor-specific antigens absent from normal cells <xref rid="b0005" ref-type="bibr">[1]</xref>. To avoid confusion, we treat the complex of mutated peptides and the major histocompatibility complex (peptide-MHC pairs, pMHCs) as tumor neoantigens in this study. Tumor neoantigens have been well acknowledged as the ideal targets for cancer immunotherapies, such as cancer vaccines and T-cell immunotherapies <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>. To provide an easy solution for neoantigen prediction, we have previously developed an integrated software for tumor-specific neoantigen detection (TSNAD) <xref rid="b0030" ref-type="bibr">[6]</xref>, which can provide one-stop neoantigen prediction from original whole-exome sequencing (WES) or whole-genome sequencing (WGS) data of normal/tumor samples. TSNAD v1.0 has been adopted by many other groups <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref> and remains continuously updating.</p>
    <p id="p0010">We present here TSNAD v2.0 that implements new features and improvements including (i) update all the embedded tools into the latest version, (ii) add the function of RNA-Seq data analysis including gene expression and gene fusion analyses, (iii) support two versions of reference genome (GRCh37 and GRCh38) when calling mutations, (iv) add the neoantigen prediction derived from INDELs and gene fusions, (v) replace NetMHCpan with our developed tool DeepHLApan and provide a web service of TSNAD, (vi) provide the installation method of Docker which comprises all the needed tools and reference files.</p>
  </sec>
  <sec id="s0010">
    <label>2</label>
    <title>Methods</title>
    <p id="p0015">As illustrated in <xref rid="f0005" ref-type="fig">Fig. 1</xref>, the TSNAD v2.0 consists of five modules.<fig id="f0005"><label>Fig. 1</label><caption><p>Workflow of TSNAD v2.0. Including SNV/INDEL detection, HLA allele detection, gene fusion detection, gene expression detection, and neoantigen prediction. WGS, whole-genome sequence. WES, whole-exon sequence. SNV, single nucleotide variant. HLA, human leukemia antigen.</p></caption><graphic xlink:href="gr1"/></fig></p>
    <sec id="s0015">
      <label>2.1</label>
      <title>Module 1: SNV/INDEL detection</title>
      <p id="p0020">Firstly, TSNAD v2.0 uses Trimmomatic (v0.39) <xref rid="b0065" ref-type="bibr">[13]</xref> to trim and crop raw WES/WGS reads and remove artifacts that will be harmful to the subsequent data processing. Then, BWA (v0.7.17) <xref rid="b0070" ref-type="bibr">[14]</xref> is used for mapping short sequences to a reference genome (GRCh37 or GRCh38). SAMtools (v1.13) <xref rid="b0075" ref-type="bibr">[15]</xref> is used to transform sequencing data format from SAM (sequence alignment/map) to BAM (binary alignment/map), which could save an enormous amount of storage space. GATK (v4.2.0.0) <xref rid="b0080" ref-type="bibr">[16]</xref> is used to remove repeat sequences and recalibrate the base quality score to create the final BAM file. The Mutect2 module of GATK is used to call SNVs/INDELs.</p>
    </sec>
    <sec id="s0020">
      <label>2.2</label>
      <title>Module 2: HLA allele detection</title>
      <p id="p0025">The input data used for human leukocyte antigen (HLA) allele detection is the cleaned fastq files created by Trimmomatic in the first module. OptiType (v1.3.5) <xref rid="b0085" ref-type="bibr">[17]</xref> is used for HLA allele identification.</p>
    </sec>
    <sec id="s0025">
      <label>2.3</label>
      <title>Module 3: Fusion detection</title>
      <p id="p0030">The detection of fusions is based on the RNA-Seq data. STAR (v2.7) aligner <xref rid="b0090" ref-type="bibr">[18]</xref> is used for mapping reads to the reference genome, Arriba (v1.1.0) <xref rid="b0095" ref-type="bibr">[19]</xref> is then used for fusion detection. Compared with other fusion detectors such as STAR-fusion <xref rid="b0100" ref-type="bibr">[20]</xref>, Arriba is both quicker and more accurate.</p>
    </sec>
    <sec id="s0030">
      <label>2.4</label>
      <title>Module 4: Gene expression detection</title>
      <p id="p0035">The gene expression detection is achieved by HISAT2 (v2.2.1) <xref rid="b0140" ref-type="bibr">[28]</xref>, SAMtools (v1.13), and Stringtie (v2.1.6) <xref rid="b0145" ref-type="bibr">[29]</xref>. HISAT2 is used to map next-generation sequencing reads to human genomes, SAMtools plays the same role as in module 1 and Stringtie is used to assemble the RNA-Seq alignments into potential transcripts and provide the expression result.</p>
    </sec>
    <sec id="s0035">
      <label>2.5</label>
      <title>Module 5: Neoantigen prediction</title>
      <p id="p0040">Neoantigen prediction module is the most important part of TSNAD v2.0. With the identified SNVs/INDELs, VEP (v104) <xref rid="b0105" ref-type="bibr">[21]</xref> is used to annotate them to obtain the mutation information at the amino acid level. Take the advantage of in-home scripts, all mutant peptides cover the mutations with length ranges from 8 to 11 are then extracted. Combining the mutant peptides with detected HLA alleles, DeepHLApan (v1.1) <xref rid="b0110" ref-type="bibr">[22]</xref> is used for the final neoantigen prediction. In general, all the peptide-MHC pairs with binding score &gt;0.5 and immunogenic score &gt; 0.5 are potential neoantigens. Further, we suggest that the peptide-MHC pairs with immunogenic score &gt;0.5 and binding score rank top 20 across the different lengths of peptides are high-confidence neoantigens within one sample (i.e. 80 high-confidence neoantigens each sample). The prediction process of fusion-derived neoantigens is similar, with the difference that the neo-peptides generates by gene fusions are provided by Arriba. The gene expression detected in module 4 is a filter to remove the neoantigens generated by the mutations in unexpressed genes (TPM &lt; 1), which could improve the accuracy of the final prediction results.</p>
      <p id="p0045">The extracellular mutations of membrane proteins are not the typical neoantigens as defined, however, they could also be potential tumor-specific targets so we retained the function of extracellular mutations identification that TSNAD v1.0 provides. The SNVs/INDELs located in the extracellular domains of membrane proteins would be stored in a separate file.</p>
    </sec>
  </sec>
  <sec id="s0040">
    <label>3</label>
    <title>Results</title>
    <sec id="s0045">
      <label>3.1</label>
      <title>Features update from TSNAD v1.0</title>
      <p id="p0050">The first version of TSNAD takes advantage of the best practices of the GATK <xref rid="b0080" ref-type="bibr">[16]</xref> and NetMHCpan <xref rid="b0115" ref-type="bibr">[23]</xref> to predict neoantigens from the whole genome/exome sequencing data of tumor-normal pairs, comprising other tools such as Trimmomatic <xref rid="b0065" ref-type="bibr">[13]</xref>, BWA <xref rid="b0070" ref-type="bibr">[14]</xref>, SAMtools <xref rid="b0075" ref-type="bibr">[15]</xref>, Picard <xref rid="b0120" ref-type="bibr">[24]</xref>, ANNOVAR <xref rid="b0125" ref-type="bibr">[25]</xref>. SOAP-HLA <xref rid="b0130" ref-type="bibr">[26]</xref> and TMHMM <xref rid="b0135" ref-type="bibr">[27]</xref>. As time goes by, some of the tools are updated or deprecated so we improve their version or replace them with other tools, respectively. The detailed adjustment is as follows: (i) Trimmomatic, BWA, SAMtools, and GATK are updated to the latest version. (ii) Picard is embedded in the latest version of GATK as a module. (iii) ANNOVAR is replaced by the latest version of VEP <xref rid="b0105" ref-type="bibr">[21]</xref>, which is more suitable in our pipeline. (iv) NetMHCpan is replaced by DeepHLApan <xref rid="b0110" ref-type="bibr">[22]</xref> which would be discussed later.</p>
      <p id="p0055">TSNAD v1.0 only supports the reference genome GRCh37, we add the selection of GRCh38 when identifying neoantigens by replacing SOAP-HLA with OptiType which is able to detect HLA alleles under both reference genomes <xref rid="b0085" ref-type="bibr">[17]</xref>. Normally, the expression of genes in tumors should be considered when predicting the potential neoantigens of patients since no neoantigens would be generated from unexpressed genes. We provide the new function of RNA-Seq analysis by combining HISAT2 <xref rid="b0140" ref-type="bibr">[28]</xref> and Stringtie <xref rid="b0145" ref-type="bibr">[29]</xref> into the pipeline to detect gene expression at the transcription level. Besides, we also provide the new function to predict neoantigens derived from mutations more than single nucleotide variants (SNVs), such as INDELs and gene fusions. The INDEL calling is also called by the Mutect2 module of GATK. The gene fusion analysis is achieved by combining STAR <xref rid="b0090" ref-type="bibr">[18]</xref> and Arriba <xref rid="b0095" ref-type="bibr">[19]</xref>. To note, the gene expression and gene fusion analysis would only be performed with RNA-Seq data.</p>
      <p id="p0060">The core part of TSNAD is the prediction that whether one pair of peptide-MHC is potential neoantigen and NetMHCpan is used to achieve this purpose in TSNAD v1.0. However, the mechanism of how neoantigens inducing T-cell response is complex and more than peptide-MHC binding which is the function that NetMHCpan provides. So we replace NetMHCpan with our recently developed tool DeepHLApan <xref rid="b0110" ref-type="bibr">[22]</xref> for neoantigen prediction, which considers both peptide-MHC binding and the potential immunogenicity of the presented peptide-MHC pairs. It significantly reduced the false positives when predicting neoantigens and was more suitable to be embedded in the updated version of TSNAD.</p>
    </sec>
    <sec id="s0050">
      <label>3.2</label>
      <title>TSNAD v2.0 achieves high performance on TESLA data</title>
      <p id="p0065">Standard datasets are of critical importance to provide a benchmark to evaluate software performance. Recently, the Tumor Neoantigen Selection Alliance (TESLA), a global community provide a standard dataset for the comparison of neoantigen prediction tools <xref rid="b0150" ref-type="bibr">[30]</xref>. In their study, 608 predicted neoantigens, which are derived from six patients and predicted by tools from 28 unique teams are tested for immunogenicity and 37 (6.1%) of them were found to be immunogenic.</p>
      <p id="p0070">Due to the data availability, we obtained the WES, tumor RNA-Seq, and clinical-grade HLA typing of five patients (three melanoma patients with ID 1_TESLA, 2_TESLA, and 3_TESLA and two non-small cell lung carcinoma patients with ID 12_TESLA and 16_TESLA) from Synapse with identifier syn21048999. Under different selection of the reference genome, the number of mutations of each patient identified by TSNAD v2.0 is similar (<xref rid="t0005" ref-type="table">Table1</xref>). Results show that melanoma patients have more SNVs than non-small cell lung carcinoma patients while having a similar number of INDELs and gene fusions.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>The number of SNVs, INDELs, and Fusions of five TESLA samples, respectively.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reference genome</th><th>ID</th><th>#SNVs</th><th>#INDELs</th><th>#Fusions</th></tr></thead><tbody><tr><td rowspan="5">GRCh38</td><td>1_TESLA</td><td>122</td><td>16</td><td>11</td></tr><tr><td>2_TESLA</td><td>440</td><td>24</td><td>18</td></tr><tr><td>3_TESLA</td><td>826</td><td>19</td><td>10</td></tr><tr><td>12_TESLA</td><td>62</td><td>14</td><td>12</td></tr><tr><td>16_TESLA</td><td>59</td><td>14</td><td>6</td></tr><tr><td colspan="5">  </td></tr><tr><td rowspan="5">GRCh37</td><td>1_TESLA</td><td>128</td><td>15</td><td>5</td></tr><tr><td>2_TESLA</td><td>450</td><td>24</td><td>19</td></tr><tr><td>3_TESLA</td><td>862</td><td>20</td><td>10</td></tr><tr><td>12_TESLA</td><td>65</td><td>15</td><td>8</td></tr><tr><td>16_TESLA</td><td>58</td><td>13</td><td>10</td></tr></tbody></table></table-wrap></p>
      <p id="p0075">80 high-confidence neoantigens for each sample and 400 in total for five samples are predicted by TSNAD v2.0. However, among the 400 predicted neoantigens, only 23/30 peptide-MHC pairs have been tested by TESLA, and 5/5 of them (21.7%/16.7%) are validated as immunogenic under the reference genome GRCh38/GRCh37, respectively (<xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="s0075" ref-type="sec">S1 and S2</xref>). Besides, we also evaluate the prediction performance of TSNAD v2.0 when selecting peptide-MHC pairs ranked top 10, 30, 40, and 50 as high-confidence neoantigens, respectively. The poorest performance of TSNAD v2.0 by selecting the top 10 peptide-MHC pairs under the reference genome GRCh38 (11.1%) is also greater than 6.1%, the overall positive rate of TESLA dataset (<xref rid="t0020" ref-type="table">Table 4</xref>). We also evaluated the predicted binding scores for the 608 tested peptide-MHC pairs by applying TSNAD v2.0. The predicted binding scores of immunogenic peptide-MHC pairs are significantly greater than non-immunogenic peptide-MHC pairs no matter in all TESLA dataset (608 peptide-MHC pairs, Wilcoxon test, p = 1.2 × 10<sup>-7</sup>) or the peptide-MHC pairs with predicted immunogenic scores greater than 0.5 (241 peptide-MHC pairs, Wilcoxon test, p = 0.026) (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). All the results support the predicted reliability of TSNAD v2.0.<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>The 23 validated peptide-MHC pairs from 400 predicted neoantigens under the reference genome GRCh38. The detailed information of the ‘Mutation’ column includes the gene name, mutation position in a protein, and the position of mutated amino acid in the peptide.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>ID</th><th>Mutation</th><th>HLA</th><th>Peptide</th><th>Binding score</th><th>Immunogenic score</th><th>Rank</th><th>Validation</th></tr></thead><tbody><tr><td>1_TESLA</td><td>ACE_S167F_1</td><td>HLA-A02:01</td><td>FLDPDLTNI</td><td align="char">0.9972</td><td align="char">0.7211</td><td>16</td><td>TRUE</td></tr><tr><td>2_TESLA</td><td>PBRM1_K1072E_5</td><td>HLA-B57:01</td><td>KSFKEIKLW</td><td align="char">0.9999</td><td align="char">0.9160</td><td>0</td><td>TRUE</td></tr><tr><td>2_TESLA</td><td>ATP13A3_S899F_1</td><td>HLA-A02:01</td><td>FLSELEASV</td><td align="char">0.9996</td><td align="char">0.7721</td><td>1</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>SEC61A1_R231W_9</td><td>HLA-B57:01</td><td>RTDKVRALW</td><td align="char">0.9995</td><td align="char">0.9772</td><td>2</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>CFAP20_P74S_8</td><td>HLA-B57:01</td><td>KTLGIKLSF</td><td align="char">0.9994</td><td align="char">0.9450</td><td>3</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>ME1_E227K_4</td><td>HLA-A02:01</td><td>FLDKFMEAV</td><td align="char">0.9992</td><td align="char">0.7303</td><td>4</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>G6PD_A149V_9</td><td>HLA-A02:01</td><td>ALPPTVYEV</td><td align="char">0.9976</td><td align="char">0.7410</td><td>14</td><td>TRUE</td></tr><tr><td>2_TESLA</td><td>OPA1_V585G_5</td><td>HLA-B57:01</td><td>LSLAGSDCFW</td><td align="char">0.9996</td><td align="char">0.9944</td><td>7</td><td>FALSE</td></tr><tr><td>3_TESLA</td><td>SLC4A2_P363L_4</td><td>HLA-B08:01</td><td>WGKLHVASL</td><td align="char">0.9979</td><td align="char">0.7932</td><td>8</td><td>FALSE</td></tr><tr><td>3_TESLA</td><td>PLXNA3_E1312K_3</td><td>HLA-A03:01</td><td>GIKAHPVLK</td><td align="char">0.9979</td><td align="char">0.6438</td><td>9</td><td>FALSE</td></tr><tr><td>3_TESLA</td><td>KDM6B_P776L_3</td><td>HLA-A03:01</td><td>ALLPPPPLAK</td><td align="char">0.9993</td><td align="char">0.5449</td><td>10</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>NAA25_R14L_8</td><td>HLA-C05:01</td><td>VQDPNDRLL</td><td align="char">0.9999</td><td align="char">0.9719</td><td>3</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>HMGB3_P96R_2</td><td>HLA-B27:05</td><td>RRPSGFFLF</td><td align="char">0.9995</td><td align="char">0.7617</td><td>8</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>POFUT2_V241L_5</td><td>HLA-B27:05</td><td>RRSMLFARH</td><td align="char">0.9994</td><td align="char">0.9010</td><td>12</td><td>TRUE</td></tr><tr><td>16_TESLA</td><td>PSD4_R868H_5</td><td>HLA-C05:01</td><td>TADWHLYLF</td><td align="char">0.9993</td><td align="char">0.9647</td><td>15</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>EBF4_G327R_2</td><td>HLA-B27:05</td><td>KRCPGRFVY</td><td align="char">0.9992</td><td align="char">0.8832</td><td>17</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>COL5A2_P1266T_4</td><td>HLA-C05:01</td><td>KTDTGVHATL</td><td align="char">1.0000</td><td align="char">0.9491</td><td>0</td><td>TRUE</td></tr><tr><td>16_TESLA</td><td>HMGB3_P96R_3</td><td>HLA-B27:05</td><td>KRRPSGFFLF</td><td align="char">1.0000</td><td align="char">0.7072</td><td>1</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>SNX7_R234I_8</td><td>HLA-B27:05</td><td>SRMGQTVIAV</td><td align="char">0.9999</td><td align="char">0.5118</td><td>5</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>PLXDC1_V290F_10</td><td>HLA-B27:05</td><td>HRIELDPSKF</td><td align="char">0.9999</td><td align="char">0.9010</td><td>6</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>POFUT2_V241L_5</td><td>HLA-B27:05</td><td>RRSMLFARHL</td><td align="char">0.9999</td><td align="char">0.9052</td><td>7</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>PSD4_R868H_7</td><td>HLA-B27:05</td><td>LRTADWHLYL</td><td align="char">0.9999</td><td align="char">0.9148</td><td>8</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>ATR_D1243Y_3</td><td>HLA-B27:05</td><td>NRYAVQDFLH</td><td align="char">0.9998</td><td align="char">0.6015</td><td>13</td><td>FALSE</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>The 30 validated peptide-MHC pairs from 400 predicted neoantigens under the reference genome GRCh37. The detailed information of the ‘Mutation’ column includes the gene name, mutation position in a protein, and the position of mutated amino acid in the peptide.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>ID</th><th>Mutation</th><th>HLA</th><th>Peptide</th><th>Binding score</th><th>Immunogenic score</th><th>Rank</th><th>Validation</th></tr></thead><tbody><tr><td>1_TESLA</td><td>ACE_S167F_1</td><td>HLA-A02:01</td><td>FLDPDLTNI</td><td align="char">0.9972</td><td align="char">0.7211</td><td>19</td><td>TRUE</td></tr><tr><td>2_TESLA</td><td>ATP13A3_S899F_1</td><td>HLA-A02:01</td><td>FLSELEASV</td><td align="char">0.9996</td><td align="char">0.7721</td><td>1</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>SEC61A1_R231W_9</td><td>HLA-B57:01</td><td>RTDKVRALW</td><td align="char">0.9995</td><td align="char">0.9772</td><td>2</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>C16orf80_P74S_8</td><td>HLA-B57:01</td><td>KTLGIKLSF</td><td align="char">0.9994</td><td align="char">0.9450</td><td>3</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>ME1_E227K_4</td><td>HLA-A02:01</td><td>FLDKFMEAV</td><td align="char">0.9992</td><td align="char">0.7303</td><td>4</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>ABCC1_T645I_1</td><td>HLA-B57:01</td><td>IVRNATFTW</td><td align="char">0.9991</td><td align="char">0.9437</td><td>5</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>OPA1_V585G_5</td><td>HLA-B57:01</td><td>LSLAGSDCFW</td><td align="char">0.9996</td><td align="char">0.9944</td><td>7</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>ABCC1_T645I_2</td><td>HLA-B57:01</td><td>IIVRNATFTW</td><td align="char">0.9995</td><td align="char">0.9404</td><td>10</td><td>FALSE</td></tr><tr><td>2_TESLA</td><td>PBRM1_K1047E_5</td><td>HLA-B57:01</td><td>KSFKEIKLW</td><td align="char">0.9999</td><td align="char">0.9160</td><td>0</td><td>TRUE</td></tr><tr><td>2_TESLA</td><td>G6PD_A179V_9</td><td>HLA-A02:01</td><td>ALPPTVYEV</td><td align="char">0.9976</td><td align="char">0.7410</td><td>15</td><td>TRUE</td></tr><tr><td>3_TESLA</td><td>SLC4A2_P363L_4</td><td>HLA-B08:01</td><td>WGKLHVASL</td><td align="char">0.9979</td><td align="char">0.7932</td><td>8</td><td>FALSE</td></tr><tr><td>3_TESLA</td><td>PLXNA3_E1312K_3</td><td>HLA-A03:01</td><td>GIKAHPVLK</td><td align="char">0.9979</td><td align="char">0.6438</td><td>9</td><td>FALSE</td></tr><tr><td>3_TESLA</td><td>KDM6B_P776L_3</td><td>HLA-A03:01</td><td>ALLPPPPLAK</td><td align="char">0.9993</td><td align="char">0.5449</td><td>10</td><td>FALSE</td></tr><tr><td>12_TESLA</td><td>CYP27A1_G367C_8</td><td>HLA-A02:01</td><td>ALHEEVVCV</td><td align="char">0.9973</td><td align="char">0.7153</td><td>11</td><td>FALSE</td></tr><tr><td>12_TESLA</td><td>MFSD7_N179D_4</td><td>HLA-A02:01</td><td>LVADVLSPV</td><td align="char">0.9956</td><td align="char">0.5472</td><td>15</td><td>FALSE</td></tr><tr><td>12_TESLA</td><td>HELZ2_A2160V_9</td><td>HLA-A02:01</td><td>KLNPSQNVV</td><td align="char">0.9947</td><td align="char">0.6994</td><td>19</td><td>FALSE</td></tr><tr><td>12_TESLA</td><td>A1BG_H362R_6</td><td>HLA-A02:01</td><td>ALFELRNISV</td><td align="char">0.9982</td><td align="char">0.5865</td><td>14</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>NAA25_R14L_8</td><td>HLA-C05:01</td><td>VQDPNDRLL</td><td align="char">0.9999</td><td align="char">0.9719</td><td>3</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>HMGB3_P96R_2</td><td>HLA-B27:05</td><td>RRPSGFFLF</td><td align="char">0.9995</td><td align="char">0.7617</td><td>8</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>PLCL1_P827H_5</td><td>HLA-B27:05</td><td>YRHVHLRSF</td><td align="char">0.9994</td><td align="char">0.9491</td><td>10</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>PSD4_R868H_5</td><td>HLA-C05:01</td><td>TADWHLYLF</td><td align="char">0.9993</td><td align="char">0.9647</td><td>14</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>EBF4_G327R_2</td><td>HLA-B27:05</td><td>KRCPGRFVY</td><td align="char">0.9992</td><td align="char">0.8832</td><td>16</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>HMGB3_P96R_3</td><td>HLA-B27:05</td><td>KRRPSGFFLF</td><td align="char">1.0000</td><td align="char">0.7072</td><td>1</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>SNX7_R234I_8</td><td>HLA-B27:05</td><td>SRMGQTVIAV</td><td align="char">0.9999</td><td align="char">0.5118</td><td>5</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>PLXDC1_V290F_10</td><td>HLA-B27:05</td><td>HRIELDPSKF</td><td align="char">0.9999</td><td align="char">0.9010</td><td>6</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>POFUT2_V241L_5</td><td>HLA-B27:05</td><td>RRSMLFARHL</td><td align="char">0.9999</td><td align="char">0.9052</td><td>7</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>PSD4_R868H_7</td><td>HLA-B27:05</td><td>LRTADWHLYL</td><td align="char">0.9999</td><td align="char">0.9148</td><td>8</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>ATR_D1243Y_3</td><td>HLA-B27:05</td><td>NRYAVQDFLH</td><td align="char">0.9998</td><td align="char">0.6015</td><td>13</td><td>FALSE</td></tr><tr><td>16_TESLA</td><td>POFUT2_V241L_5</td><td>HLA-B27:05</td><td>RRSMLFARH</td><td align="char">0.9994</td><td align="char">0.9010</td><td>11</td><td>TRUE</td></tr><tr><td>16_TESLA</td><td>COL5A2_P1266T_4</td><td>HLA-C05:01</td><td>KTDTGVHATL</td><td align="char">1.0000</td><td align="char">0.9491</td><td>0</td><td>TRUE</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0020"><label>Table 4</label><caption><p>The performance of TSNAD v2.0 under different selection criterias.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reference genome</th><th>Selection criteria</th><th>#Tested</th><th>#TRUE</th><th>Accuracy</th></tr></thead><tbody><tr><td rowspan="5">GRCh38</td><td>Top10</td><td>18</td><td>2</td><td align="char">11.1%</td></tr><tr><td>Top20</td><td>23</td><td>5</td><td align="char">21.7%</td></tr><tr><td>Top30</td><td>27</td><td>5</td><td align="char">18.5%</td></tr><tr><td>Top40</td><td>33</td><td>6</td><td align="char">18.2%</td></tr><tr><td>Top50</td><td>40</td><td>6</td><td align="char">15.0%</td></tr><tr><td colspan="5">  </td></tr><tr><td rowspan="5">GRCh37</td><td>Top10</td><td>17</td><td>2</td><td align="char">11.8%</td></tr><tr><td>Top20</td><td>30</td><td>5</td><td align="char">16.7%</td></tr><tr><td>Top30</td><td>35</td><td>5</td><td align="char">14.3%</td></tr><tr><td>Top40</td><td>43</td><td>5</td><td align="char">11.6%</td></tr><tr><td>Top50</td><td>49</td><td>6</td><td align="char">12.2%</td></tr></tbody></table></table-wrap><fig id="f0010"><label>Fig. 2</label><caption><p>The comparison of predicted binding score between immunogenic peptide-MHC pairs and non-immunogenic peptide-MHC pairs. There are 37 immunogenic peptide-MHC pairs and 571 non-immunogenic peptide-MHC pairs in all TESLA dataset, among which 12 immunogenic peptide-MHC pairs and 229 non-immunogenic peptide-MHC pairs with predicted immunogenic score greater than 0.5.</p></caption><graphic xlink:href="gr2"/></fig></p>
    </sec>
    <sec id="s0055">
      <label>3.3</label>
      <title>Improved usability of TSNAD v2.0</title>
      <p id="p0080">For better usage of TSNAD v2.0, we provide the Docker version of TSNAD v2.0 for local installation and usage. It’s easy to install TSNAD v2.0 by one command: docker pull biopharm/tsnad:latest</p>
      <p id="p0085">And given a directory <italic>samples</italic> including WES/WGS files (the files would be better to rename as <italic>normal_R1.fastq.gz</italic>, <italic>normal_R2.fastq.gz</italic>, <italic>tumor_R1.fastq.gz</italic>, and <italic>tumor_R2.fastq.gz</italic>), the following commands could achieve the purpose of neoantigen prediction:</p>
      <p id="p0090">docker run -it -v [dir of WES/WGS]/:/home/tsnad/samples -v [dir of RNA-Seq]:/home/tsnad/RNA-seq -v [output dir]:/home/tsnad/results biopharm/tsnad:latest /bin/bash</p>
      <p id="p0095">cd /home/tsnad</p>
      <p id="p0100">bash uncompress.sh</p>
      <p id="p0105">python TSNAD.py -I samples/ -R RNA-seq/ -V [grch37/grch38] -O results/</p>
      <p id="p0110">All the results would be stored in the directory <italic>results</italic>, and the predicted neoantigen would be stored in the directory <italic>deephlapan_results</italic>.</p>
      <p id="p0115">To generate useable neoantigen predictions, the minimum depth should be 15 × for WGS and 50 × for WES, the recommended depth should be 30 × for WGS and 100 × for WES. For sample TESLA_1 with WES tumor/normal data and RNA-Seq data, it takes about 50 h to finish neoantigen prediction in the Ubuntu system with 64G memory and 512G hard disk space.</p>
      <p id="p0120">Besides, we also provide a web service of TSNAD v2.0 which supports neoantigens prediction given mutations and HLA alleles (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). The mutations should be formatted in the VCF file which is the file format of mutation results from the widely used best practice of GATK. We will support more file formats if required in the future. Compared with stand-alone pipelines, the web service of TSNAD v2.0 only including DeepHLApan and some in-house scripts for processing data (i.e. the function that module 5 provides), it's more suitable for the situation that users already have mutation file and HLA alleles and do not need to analyze the potential fusion-derived neoantigens or gene expression. We would try to provide the full function of TSNAD in the future update of the web service by taking advantage of cloud storage and cloud computing.<fig id="f0015"><label>Fig. 3</label><caption><p>The web service of TSNAD v2.0. Users could provide the mutations (VCF format) and HLA alleles to predict potential neoantigens. The version of the reference genome is selectable and email is optional.</p></caption><graphic xlink:href="gr3"/></fig></p>
    </sec>
  </sec>
  <sec id="s0060">
    <label>4</label>
    <title>Conclusions</title>
    <p id="p0125">TSNAD v2.0 could provide one-stop neoantigen prediction from original WES/WGS and RNA-Seq data of normal/tumor samples. In this version, we update or replace most of the embedded tools with the latest versions or more suitable tools. Besides, it supports the choice of different versions of reference genomes when calling mutations, and also provides the analysis of INDELs, gene fusions, and gene expression. The most important change is the integration of DeepHLApan, which is the deep learning based prediction method for both peptide-MHC binding and the potential immunogenicity of the presented peptide-MHC complex. And the web service and Docker version of TSNAD v2.0 would provide an easy solution for tumor-specific neoantigen prediction.</p>
    <p id="p0130">Though DeepHLApan considers both binding and immunogenicity of peptide-MHC pairs, more effort should be put into T-cell receptor (TCR)-pMHC interaction to understand the mechanism that pMHC inducing T-cell response for predicting high-confidence neoantigens. Therefore, the future update of TSNAD should be a more complex and precise neoantigen prediction pipeline containing TCR sequencing and TCR-pMHC binding prediction model.</p>
    <p id="p0135">Code availability</p>
    <p id="p0140">The source code of TSNAD v2.0 is freely available at <ext-link ext-link-type="uri" xlink:href="https://github.com/jiujiezz/tsnad" id="ir015">https://github.com/jiujiezz/tsnad</ext-link>. The Docker version of TSNAD v2.0 is available at <ext-link ext-link-type="uri" xlink:href="https://hub.docker.com/r/biopharm/tsnad" id="ir020">https://hub.docker.com/r/biopharm/tsnad</ext-link>. The web service of TSNAD v2.0 is available at <ext-link ext-link-type="uri" xlink:href="http://biopharm.zju.edu.cn/tsnad" id="ir025">http://biopharm.zju.edu.cn/tsnad</ext-link>.</p>
  </sec>
  <sec id="s0065">
    <title>CRediT authorship contribution statement</title>
    <p id="p0145"><bold>Zhan Zhou:</bold> Conceptualization, Funding acquisition, Methodology, Software, Supervision, Writing – original draft, Writing - review &amp; editing. <bold>Jingcheng Wu:</bold> Data curation, Formal analysis, Methodology, Software, Validation, Writing – original draft, Writing - review &amp; editing. <bold>Jianan Ren:</bold> Investigation, Software. <bold>Wenfan Chen:</bold> Formal analysis. <bold>Wenyi Zhao:</bold> Formal analysis. <bold>Xun Gu:</bold> Conceptualization, Methodology. <bold>Ying Chi:</bold> Conceptualization, Methodology. <bold>Qiaojun He:</bold> Resources, Validation. <bold>Bo Yang:</bold> Resources, Validation. <bold>Jian Wu:</bold> Conceptualization, Supervision, Writing - review &amp; editing. <bold>Shuqing Chen:</bold> Conceptualization, Funding acquisition, Supervision, Writing - review &amp; editing.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Declaration of Competing Interest</title>
    <p id="p0150">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p>
  </sec>
</body>
<back>
  <ref-list id="bi005">
    <title>References</title>
    <ref id="b0005">
      <label>1</label>
      <element-citation publication-type="journal" id="h0005">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>C.H.</given-names>
          </name>
          <name>
            <surname>Yelensky</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Jooss</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>T.A.</given-names>
          </name>
        </person-group>
        <article-title>Update on tumor neoantigens and their utility: why it is good to be different</article-title>
        <source>Trends Immunol</source>
        <volume>39</volume>
        <year>2018</year>
        <fpage>536</fpage>
        <lpage>548</lpage>
        <pub-id pub-id-type="doi">10.1016/j.it.2018.04.005</pub-id>
        <pub-id pub-id-type="pmid">29751996</pub-id>
      </element-citation>
    </ref>
    <ref id="b0010">
      <label>2</label>
      <element-citation publication-type="journal" id="h0010">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>Y.C.</given-names>
          </name>
          <name>
            <surname>Robbins</surname>
            <given-names>P.F.</given-names>
          </name>
        </person-group>
        <article-title>Cancer immunotherapy targeting neoantigens</article-title>
        <source>Semin Immunol</source>
        <volume>28</volume>
        <year>2016</year>
        <fpage>22</fpage>
        <lpage>27</lpage>
        <pub-id pub-id-type="doi">10.1016/j.smim.2015.11.002</pub-id>
        <pub-id pub-id-type="pmid">26653770</pub-id>
      </element-citation>
    </ref>
    <ref id="b0015">
      <label>3</label>
      <element-citation publication-type="journal" id="h0015">
        <person-group person-group-type="author">
          <name>
            <surname>Tran</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Robbins</surname>
            <given-names>P.F.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Y.-C.</given-names>
          </name>
          <name>
            <surname>Prickett</surname>
            <given-names>T.D.</given-names>
          </name>
          <name>
            <surname>Gartner</surname>
            <given-names>J.J.</given-names>
          </name>
          <name>
            <surname>Jia</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>T-cell transfer therapy targeting mutant KRAS in cancer</article-title>
        <source>N Engl J Med</source>
        <volume>375</volume>
        <year>2016</year>
        <fpage>2255</fpage>
        <lpage>2262</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa1609279</pub-id>
        <pub-id pub-id-type="pmid">27959684</pub-id>
      </element-citation>
    </ref>
    <ref id="b0020">
      <label>4</label>
      <element-citation publication-type="journal" id="h0020">
        <person-group person-group-type="author">
          <name>
            <surname>Sahin</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Derhovanessian</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Kloke</surname>
            <given-names>B.P.</given-names>
          </name>
          <name>
            <surname>Simon</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Löwer</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</article-title>
        <source>Nature</source>
        <volume>547</volume>
        <year>2017</year>
        <fpage>222</fpage>
        <lpage>226</lpage>
        <pub-id pub-id-type="doi">10.1038/nature23003</pub-id>
        <pub-id pub-id-type="pmid">28678784</pub-id>
      </element-citation>
    </ref>
    <ref id="b0025">
      <label>5</label>
      <element-citation publication-type="journal" id="h0025">
        <person-group person-group-type="author">
          <name>
            <surname>Ott</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Keskin</surname>
            <given-names>D.B.</given-names>
          </name>
          <name>
            <surname>Shukla</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bozym</surname>
            <given-names>D.J.</given-names>
          </name>
        </person-group>
        <article-title>An immunogenic personal neoantigen vaccine for patients with melanoma</article-title>
        <source>Nature</source>
        <volume>547</volume>
        <year>2017</year>
        <fpage>217</fpage>
        <lpage>221</lpage>
        <pub-id pub-id-type="doi">10.1038/nature22991</pub-id>
        <pub-id pub-id-type="pmid">28678778</pub-id>
      </element-citation>
    </ref>
    <ref id="b0030">
      <label>6</label>
      <element-citation publication-type="journal" id="h0030">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Lyu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>TSNAD: An integrated software for cancer somatic mutation and tumour-specific neoantigen detection</article-title>
        <source>R Soc Open Sci</source>
        <volume>4</volume>
        <year>2017</year>
        <object-id pub-id-type="publisher-id">170050</object-id>
        <pub-id pub-id-type="doi">10.1098/rsos.170050</pub-id>
      </element-citation>
    </ref>
    <ref id="b0035">
      <label>7</label>
      <element-citation publication-type="journal" id="h0035">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Jie</surname>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Q.</given-names>
          </name>
        </person-group>
        <article-title>Towards In silico prediction of the immune-checkpoint blockade response</article-title>
        <source>Trends Pharmacol Sci</source>
        <volume>38</volume>
        <year>2017</year>
        <fpage>1041</fpage>
        <lpage>1051</lpage>
        <pub-id pub-id-type="doi">10.1016/j.tips.2017.10.002</pub-id>
        <pub-id pub-id-type="pmid">29089139</pub-id>
      </element-citation>
    </ref>
    <ref id="b0040">
      <label>8</label>
      <element-citation publication-type="journal" id="h0040">
        <person-group person-group-type="author">
          <name>
            <surname>González</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Volkova</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Beer</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Gerstung</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Immuno-oncology from the perspective of somatic evolution</article-title>
        <source>Semin Cancer Biol</source>
        <volume>52</volume>
        <year>2018</year>
        <fpage>75</fpage>
        <lpage>85</lpage>
        <pub-id pub-id-type="doi">10.1016/j.semcancer.2017.12.001</pub-id>
        <pub-id pub-id-type="pmid">29223477</pub-id>
      </element-citation>
    </ref>
    <ref id="b0045">
      <label>9</label>
      <element-citation publication-type="journal" id="h0045">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <article-title>TSNAdb: A database for tumor-specific neoantigens from immunogenomics data analysis</article-title>
        <source>Genom. Proteom. Bioinforma</source>
        <volume>16</volume>
        <year>2018</year>
        <fpage>276</fpage>
        <lpage>282</lpage>
        <pub-id pub-id-type="doi">10.1016/j.gpb.2018.06.003</pub-id>
      </element-citation>
    </ref>
    <ref id="b0050">
      <label>10</label>
      <element-citation publication-type="journal" id="h0050">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Q.</given-names>
          </name>
        </person-group>
        <article-title>Toward in silico identification of tumor neoantigens in immunotherapy</article-title>
        <source>Trends Mol Med</source>
        <volume>25</volume>
        <year>2019</year>
        <fpage>980</fpage>
        <lpage>992</lpage>
        <pub-id pub-id-type="doi">10.1016/j.molmed.2019.08.001</pub-id>
        <pub-id pub-id-type="pmid">31494024</pub-id>
      </element-citation>
    </ref>
    <ref id="b0055">
      <label>11</label>
      <element-citation publication-type="journal" id="h0055">
        <person-group person-group-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Selitsky</surname>
            <given-names>S.R.</given-names>
          </name>
          <name>
            <surname>Chai</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Armistead</surname>
            <given-names>P.M.</given-names>
          </name>
          <name>
            <surname>Vincent</surname>
            <given-names>B.G.</given-names>
          </name>
          <name>
            <surname>Serody</surname>
            <given-names>J.S.</given-names>
          </name>
        </person-group>
        <article-title>Alternative tumour-specific antigens</article-title>
        <source>Nat Rev Cancer</source>
        <volume>19</volume>
        <year>2019</year>
        <fpage>465</fpage>
        <lpage>478</lpage>
        <pub-id pub-id-type="doi">10.1038/s41568-019-0162-4</pub-id>
        <pub-id pub-id-type="pmid">31278396</pub-id>
      </element-citation>
    </ref>
    <ref id="b0060">
      <label>12</label>
      <element-citation publication-type="journal" id="h0060">
        <person-group person-group-type="author">
          <name>
            <surname>Richters</surname>
            <given-names>M.M.</given-names>
          </name>
          <name>
            <surname>Xia</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>K.M.</given-names>
          </name>
          <name>
            <surname>Gillanders</surname>
            <given-names>W.E.</given-names>
          </name>
          <name>
            <surname>Griffith</surname>
            <given-names>O.L.</given-names>
          </name>
          <name>
            <surname>Griffith</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Best practices for bioinformatic characterization of neoantigens for clinical utility</article-title>
        <source>Genome Med</source>
        <volume>11</volume>
        <year>2019</year>
        <fpage>56</fpage>
        <pub-id pub-id-type="doi">10.1186/s13073-019-0666-2</pub-id>
        <pub-id pub-id-type="pmid">31462330</pub-id>
      </element-citation>
    </ref>
    <ref id="b0065">
      <label>13</label>
      <element-citation publication-type="journal" id="h0065">
        <person-group person-group-type="author">
          <name>
            <surname>Bolger</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Lohse</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Usadel</surname>
            <given-names>B.</given-names>
          </name>
        </person-group>
        <article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title>
        <source>Bioinformatics</source>
        <volume>30</volume>
        <year>2014</year>
        <fpage>2114</fpage>
        <lpage>2120</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id>
        <pub-id pub-id-type="pmid">24695404</pub-id>
      </element-citation>
    </ref>
    <ref id="b0070">
      <label>14</label>
      <element-citation publication-type="journal" id="h0070">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Durbin</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Fast and accurate long-read alignment with Burrows-Wheeler transform</article-title>
        <source>Bioinformatics</source>
        <volume>26</volume>
        <year>2010</year>
        <fpage>589</fpage>
        <lpage>595</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp698</pub-id>
        <pub-id pub-id-type="pmid">20080505</pub-id>
      </element-citation>
    </ref>
    <ref id="b0075">
      <label>15</label>
      <element-citation publication-type="journal" id="h0075">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data</article-title>
        <source>Bioinformatics</source>
        <volume>27</volume>
        <year>2011</year>
        <fpage>2987</fpage>
        <lpage>2993</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btr509</pub-id>
        <pub-id pub-id-type="pmid">21903627</pub-id>
      </element-citation>
    </ref>
    <ref id="b0080">
      <label>16</label>
      <element-citation publication-type="journal" id="h0080">
        <person-group person-group-type="author">
          <name>
            <surname>McKenna</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Hanna</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Banks</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Sivachenko</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Cibulskis</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Kernytsky</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data</article-title>
        <source>Genome Res</source>
        <volume>20</volume>
        <year>2010</year>
        <fpage>1297</fpage>
        <lpage>1303</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id>
        <pub-id pub-id-type="pmid">20644199</pub-id>
      </element-citation>
    </ref>
    <ref id="b0085">
      <label>17</label>
      <element-citation publication-type="journal" id="h0085">
        <person-group person-group-type="author">
          <name>
            <surname>Szolek</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Schubert</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Mohr</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Sturm</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Feldhahn</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Kohlbacher</surname>
            <given-names>O.</given-names>
          </name>
        </person-group>
        <article-title>OptiType: precision HLA typing from next-generation sequencing data</article-title>
        <source>Bioinformatics</source>
        <volume>30</volume>
        <year>2014</year>
        <fpage>3310</fpage>
        <lpage>3316</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btu548</pub-id>
        <pub-id pub-id-type="pmid">25143287</pub-id>
      </element-citation>
    </ref>
    <ref id="b0090">
      <label>18</label>
      <element-citation publication-type="journal" id="h0090">
        <person-group person-group-type="author">
          <name>
            <surname>Dobin</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Davis</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Schlesinger</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Drenkow</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zaleski</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Jha</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>
        <source>Bioinformatics</source>
        <volume>29</volume>
        <year>2013</year>
        <fpage>15</fpage>
        <lpage>21</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id>
        <pub-id pub-id-type="pmid">23104886</pub-id>
      </element-citation>
    </ref>
    <ref id="b0095">
      <label>19</label>
      <mixed-citation publication-type="other" id="h0095">Uhrig S, Ellermann J, Walther T, Burkhardt P, Fröhlich M, Hutter B, et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res 2021:gr.257246.119. 10.1101/gr.257246.119.</mixed-citation>
    </ref>
    <ref id="b0100">
      <label>20</label>
      <element-citation publication-type="journal" id="h0100">
        <person-group person-group-type="author">
          <name>
            <surname>Haas</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Dobin</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Stransky</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Pochet</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Regev</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods</article-title>
        <source>Genome Biol</source>
        <volume>20</volume>
        <year>2019</year>
        <fpage>1</fpage>
        <lpage>16</lpage>
        <pub-id pub-id-type="doi">10.1186/s13059-019-1842-9</pub-id>
        <pub-id pub-id-type="pmid">30606230</pub-id>
      </element-citation>
    </ref>
    <ref id="b0105">
      <label>21</label>
      <element-citation publication-type="journal" id="h0105">
        <person-group person-group-type="author">
          <name>
            <surname>McLaren</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Gil</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Hunt</surname>
            <given-names>S.E.</given-names>
          </name>
          <name>
            <surname>Riat</surname>
            <given-names>H.S.</given-names>
          </name>
          <name>
            <surname>Ritchie</surname>
            <given-names>G.R.S.</given-names>
          </name>
          <name>
            <surname>Thormann</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>The ensembl variant effect predictor</article-title>
        <source>Genome Biol</source>
        <volume>17</volume>
        <year>2016</year>
        <fpage>122</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-016-0974-4</pub-id>
        <pub-id pub-id-type="pmid">27268795</pub-id>
      </element-citation>
    </ref>
    <ref id="b0110">
      <label>22</label>
      <element-citation publication-type="journal" id="h0110">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <article-title>DeepHLApan: a deep learning approach for neoantigen prediction considering both HLA-peptide binding and immunogenicity</article-title>
        <source>Front Immunol</source>
        <volume>10</volume>
        <year>2019</year>
        <fpage>2559</fpage>
        <pub-id pub-id-type="doi">10.3389/fimmu.2019.02559</pub-id>
        <pub-id pub-id-type="pmid">31736974</pub-id>
      </element-citation>
    </ref>
    <ref id="b0115">
      <label>23</label>
      <element-citation publication-type="journal" id="h0115">
        <person-group person-group-type="author">
          <name>
            <surname>Hoof</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Peters</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Sidney</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Pedersen</surname>
            <given-names>L.E.</given-names>
          </name>
          <name>
            <surname>Sette</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Lund</surname>
            <given-names>O.</given-names>
          </name>
        </person-group>
        <article-title>NetMHCpan, a method for MHC class i binding prediction beyond humans</article-title>
        <source>Immunogenetics</source>
        <volume>61</volume>
        <year>2009</year>
        <fpage>1</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="doi">10.1007/s00251-008-0341-z</pub-id>
        <pub-id pub-id-type="pmid">19002680</pub-id>
      </element-citation>
    </ref>
    <ref id="b0120">
      <label>24</label>
      <element-citation publication-type="journal" id="h0120">
        <person-group person-group-type="author">
          <name>
            <surname>Depristo</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Banks</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Poplin</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Garimella</surname>
            <given-names>K.V.</given-names>
          </name>
          <name>
            <surname>Maguire</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Hartl</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>A framework for variation discovery and genotyping using next-generation DNA sequencing data</article-title>
        <source>Nat Genet</source>
        <volume>43</volume>
        <year>2011</year>
        <fpage>491</fpage>
        <lpage>501</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.806</pub-id>
        <pub-id pub-id-type="pmid">21478889</pub-id>
      </element-citation>
    </ref>
    <ref id="b0125">
      <label>25</label>
      <element-citation publication-type="journal" id="h0125">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Hakonarson</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</article-title>
        <source>Nucleic Acids Res</source>
        <volume>38</volume>
        <year>2010</year>
        <fpage>1</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkq603</pub-id>
        <pub-id pub-id-type="pmid">19843612</pub-id>
      </element-citation>
    </ref>
    <ref id="b0130">
      <label>26</label>
      <element-citation publication-type="journal" id="h0130">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lam</surname>
            <given-names>T.W.</given-names>
          </name>
          <name>
            <surname>Yiu</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Kristiansen</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>SOAP2: an improved ultrafast tool for short read alignment</article-title>
        <source>Bioinformatics</source>
        <volume>25</volume>
        <year>2009</year>
        <fpage>1966</fpage>
        <lpage>1967</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btp336</pub-id>
        <pub-id pub-id-type="pmid">19497933</pub-id>
      </element-citation>
    </ref>
    <ref id="b0135">
      <label>27</label>
      <mixed-citation publication-type="other" id="h0135">Sonnhammer EL, von Heijne G, Krogh A. A hidden Markov model for predicting transmembrane helices in protein sequences. Int. Conf. Intell. Syst. Mol. Biol. ; ISMB., vol. 6, 1998, p. 175–82. 9783223.</mixed-citation>
    </ref>
    <ref id="b0140">
      <label>28</label>
      <element-citation publication-type="journal" id="h0140">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Langmead</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Salzberg</surname>
            <given-names>S.L.</given-names>
          </name>
        </person-group>
        <article-title>HISAT: a fast spliced aligner with low memory requirements</article-title>
        <source>Nat Methods</source>
        <volume>12</volume>
        <year>2015</year>
        <fpage>357</fpage>
        <lpage>360</lpage>
        <pub-id pub-id-type="doi">10.1038/nmeth.3317</pub-id>
        <pub-id pub-id-type="pmid">25751142</pub-id>
      </element-citation>
    </ref>
    <ref id="b0145">
      <label>29</label>
      <element-citation publication-type="journal" id="h0145">
        <person-group person-group-type="author">
          <name>
            <surname>Pertea</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Pertea</surname>
            <given-names>G.M.</given-names>
          </name>
          <name>
            <surname>Antonescu</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>T.-C.</given-names>
          </name>
          <name>
            <surname>Mendell</surname>
            <given-names>J.T.</given-names>
          </name>
          <name>
            <surname>Salzberg</surname>
            <given-names>S.L.</given-names>
          </name>
        </person-group>
        <article-title>StringTie enables improved reconstruction of a transcriptome from RNA-seq reads</article-title>
        <source>Nat Biotechnol</source>
        <volume>33</volume>
        <year>2015</year>
        <fpage>290</fpage>
        <lpage>295</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt.3122</pub-id>
        <pub-id pub-id-type="pmid">25690850</pub-id>
      </element-citation>
    </ref>
    <ref id="b0150">
      <label>30</label>
      <element-citation publication-type="journal" id="h0150">
        <person-group person-group-type="author">
          <name>
            <surname>Wells</surname>
            <given-names>D.K.</given-names>
          </name>
          <name>
            <surname>van Buuren</surname>
            <given-names>M.M.</given-names>
          </name>
          <name>
            <surname>Dang</surname>
            <given-names>K.K.</given-names>
          </name>
          <name>
            <surname>Hubbard-Lucey</surname>
            <given-names>V.M.</given-names>
          </name>
          <name>
            <surname>Sheehan</surname>
            <given-names>K.C.F.</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>K.M.</given-names>
          </name>
        </person-group>
        <article-title>Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction</article-title>
        <source>Cell</source>
        <volume>183</volume>
        <year>2020</year>
        <fpage>818</fpage>
        <lpage>834.e13</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2020.09.015</pub-id>
        <pub-id pub-id-type="pmid">33038342</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="s0075" sec-type="supplementary-material">
    <label>Appendix A</label>
    <title>Supplementary data</title>
    <p id="p0165">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0010"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.xlsx"/></supplementary-material></p>
    <p id="p0170">
      <supplementary-material content-type="local-data" id="m0005">
        <caption>
          <title>Supplementary data 2</title>
        </caption>
        <media xlink:href="mmc2.xlsx"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ak005">
    <title>Acknowledgments</title>
    <p id="p0155">This work has been supported by the <funding-source id="gp005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (Grant No. U20A20409, 31971371), the Key R&amp;D Program of Zhejiang Province (Grant No. 2020C03010), the Zhejiang Provincial Natural Science Foundation of China (Grant No. LY19H300003), the Fundamental Research Funds for the Central Universities of China, and Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare. We also thank the Research and Service Center, College of Pharmaceutical Sciences, Zhejiang University, and Alibaba Cloud for technical assistance, and Ms. Wenlin Zhang for language editing which has greatly improved the manuscript. We gratefully acknowledge the clinical contributors and data producers from the TESLA for referencing the TESLA dataset.</p>
  </ack>
  <fn-group>
    <fn id="s0070" fn-type="supplementary-material">
      <label>Appendix A</label>
      <p id="p0160">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.csbj.2021.08.016" id="ir030">https://doi.org/10.1016/j.csbj.2021.08.016</ext-link>.</p>
    </fn>
  </fn-group>
</back>
